| Title |
Coaxil (tianeptine) in the treatment of depression in Parkinson’s disease
|
|---|---|
| Published in |
Neuroscience and Behavioral Physiology, May 2007
|
| DOI | 10.1007/s11055-007-0029-0 |
| Pubmed ID | |
| Authors |
O. S. Levin |
| Abstract |
An open, non-comparative clinical study was performed to assess the efficacy and safety of tianeptine (Coaxil) in Parkinson's disease (PD). A total of 18 patients with PD were used whose clinical state increased moderately severe and more profound depression (assessed on the Hamilton and Beck scales). After three months of treatment, depression on the Hamilton depression scale was decreased by 34% and on the Beck scale by 31% compared with baseline data ((p) < 0.05). Improvements in mental status were noted in 14 of 18 patients (77%); eight patients (44%) showed more than 50% reductions on the Hamilton scale. Analysis of the structure of depressive symptomatology showed that improvement occurred because of decreases in anxiety and the severity of somatoform symptoms and, to a lesser extent, in melancholy and sleep disturbance. There was no significant change in apathy. The decrease in the severity of depression was accompanied by an improvement in the quality of life. The efficacy of Coaxil was greater in patients with less marked depressive and motor symptoms, shorter durations of illness, and less marked cognitive impairments. Coaxil was well tolerated by the patients. The data obtained here provide grounds for recommending the use of Coaxil in the treatment of depression in PD. |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Costa Rica | 1 | 2% |
| Unknown | 48 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 24% |
| Student > Bachelor | 9 | 18% |
| Other | 6 | 12% |
| Researcher | 6 | 12% |
| Student > Ph. D. Student | 5 | 10% |
| Other | 6 | 12% |
| Unknown | 6 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 26% |
| Psychology | 10 | 20% |
| Nursing and Health Professions | 6 | 12% |
| Agricultural and Biological Sciences | 4 | 8% |
| Neuroscience | 4 | 8% |
| Other | 6 | 12% |
| Unknown | 7 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2023.
All research outputs
#3,064,066
of 23,530,272 outputs
Outputs from Neuroscience and Behavioral Physiology
#12
of 192 outputs
Outputs of similar age
#7,285
of 73,068 outputs
Outputs of similar age from Neuroscience and Behavioral Physiology
#1
of 1 outputs
Altmetric has tracked 23,530,272 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 192 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 73,068 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them